Skip to main content

Table 1 Clinical and biochemical characteristics of 20 patients with type 2 diabetes at baseline and after 4 months of nateglinide or rosiglitazone therapy

From: Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

Variables

Baseline

Nateglinide

p

Baseline

Rosiglitazone

p

After 4 months

After 4 months

Median

(25th–75th)

Median

(25th–75th)

Median

(25th–75th)

Median

(25th–75th)

Body weight (kg)

67.9

(64.1–81.0)

70.0

(64.5–78.0)

0.073

69.0

(63.9–77.0)

68.9

63.6–77.9

0.984

Hba1c (%)

7.45

(7.0–8.3)

6.65

(5.7–7.8)

0.032

7.2

(6.8–8.1)

6.6

5.5–7.5

0.036

Homa Beta

40.7

(28.8–52.0)

51.3

(28.7–73.0)

0.126

33.6

(26.8–59.0)

51.6

30.9–69.9

0.005

Total-c (mg/dL)

223.5

(178.5–235.3)

194.0

(182.0–213.0)

0.036

213.0

(184.0–230.0)

211.0

201.0–245.0

0.277

HDL-c (mg/dL)

44.5

(37.8–57–8)

44.5

(34.0–55.0)

0.360

45.0

(40.0–56.0)

48.0

38.0–55.0

0.347

LDL-c (mg/dL)

144.0

(111.0–153.5)

131.5

(109.5–142.0)

0.145

152.0

(106.0–157.0)

142.0

124.0–168.0

0.355

CRP (mg/L)

5.2

(1.87–8.91)

3.79

(1.63–7.64)

0.052

4.16

(2.23–8.37)

3.10

(0.87–6.34)

0.042

TGF β (pg/mL)

44.1

(34.2–51.1)

45.3

(32.2–49.4)

0.247

42.7

(37.8–47.9)

38.3

32.0–45.8

0.001

Interleukin-6 (pg/mL)

2.54

(1.45–5.66)

2.37

(1.16–3.53)

0.108

2.71

(1.46–4.17)

2.00

1.42–3.89

0.520

leptina (ng/mL)

14.9

(7.6–21.0)

17.9

(10.0–20.8)

0.808

13.1

(6.0–19.3)

16.2

7.0–24.1

0.199

sICAM-1 (ng/mL)

233.8

(179.7–261.5)

214.9

(186.7–263.3)

0.391

223.6

(171.3–241.6)

218.0

173.8–246.0

0.573

TNF α (pg/mL)

1.71

(1.18–2.50)

1.52

(1.08–2.91)

0.235

1.49

(1.23–2.09)

1.43

1.18–2.18

0.760

fibrinogen (mg/dL)

316.0

(276.8–375.0)

336.5

(297.8–357–5)

0.433

337.0

(296–397)

322.0

(262.5–363.8)

0.024

PA-1 activity (UI/mL)

27.7

(14.4–43.8)

24.7

(14.7–40.3)

0.55

15.9

(11.6–40.0)

12.7

8.0–19.0

0.040

platelet aggregation

90.3

(80.1–96.0)

90.0

(81.0–92.6)

0.601

89.0

(76.4–94.5)

90.9

76.0–95.0

0.643

  1. Wilcoxon matched pairs tests were performed to compare the differences before and after the 4 months of therapy for each group
  2. Italic values indicate statistical significance at p < 0.05
  3. CRP reactive protein, HDL-c HDL cholesterol, LDL-c LDL-cholesterol, PAI-1 plasminogen activator inhibitor, sICAM-1 intercellular adhesion molecule-1, TGFβ transforming growth factor beta, TNFα tumor necrosis factor alfa, Total-c total cholesterol